Attached files
file | filename |
---|---|
EX-31.1 - RULE 13A-14(A)/15D-14(A) CERTIFICATION - Vaxart, Inc. | d262743dex311.htm |
EXCEL - IDEA: XBRL DOCUMENT - Vaxart, Inc. | Financial_Report.xls |
10-K - FORM 10-K - Vaxart, Inc. | d262743d10k.htm |
EX-23 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Vaxart, Inc. | d262743dex23.htm |
Exhibit 32
Nabi Biopharmaceuticals
SECTION 1350 CERTIFICATION
The undersigned officer of Nabi Biopharmaceuticals (the Company) hereby certifies that, as of the date of this statement, the Companys Annual Report on Form 10-K for the year ended December 31, 2011 (the Report) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that, to the best of his knowledge, information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of December 31, 2011 and the results of operations of the Company for the year ended December 31, 2011.
The purpose of this statement is solely to comply with Title 18, Chapter 63, Section 1350 of the United States Code, as amended by Section 906 of the Sarbanes-Oxley Act of 2002. This statement is not filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Act or any other federal or state law or regulation.
Date: March 14, 2012 | /S/ RAAFAT E.F. FAHIM, PH.D. | |||
Name: | Raafat E.F. Fahim, Ph.D. | |||
Title: | Chief Executive Officer, President and Acting Chief Financial Officer |